US-based Johnson & Johnson (J&J, NYSE: JNJ) has released its Q4 2024 financial results, reporting global sales of USD 22.52 billion, a robust 5.3% year-on-year (YOY) operational growth excluding currency fluctuations. Net profit for the quarter was USD 3.431 billion, down 17.0% YOY. For the full year, annual sales reached USD 88.821 billion, up 4.3% YOY, with net profit totaling USD 14.066 billion, a 5.6% increase YOY.
Geographical Performance
Geographically, J&J’s Q4 2024 sales in the US market reached USD 13.204 billion, up 10.0% YOY, contributing to full-year sales of USD 50.302 billion, up 8.3% YOY. In the international market, Q4 sales were USD 9.316 billion, down 0.7% YOY, with full-year sales totaling USD 38.519 billion, down 0.5% YOY.
Business Segment Performance
By business segment, Innovative Medicine sales jumped 4.4% YOY to USD 14.332 billion in Q4 2024, reaching a total of USD 56.964 billion for the year, up 4.0% YOY. Medtech sales in Q4 2024 were USD 8.188 billion, up 6.7% YOY, with full-year sales totaling USD 31.857 billion, up 4.8% YOY.
Oncology Highlights
In oncology, Darzalex (daratumumab), a multiple myeloma (MM) medicine, continued its strong performance with Q4 2024 sales of USD 3.084 billion, up 20.9% YOY, and full-year sales of USD 11.67 billion, up 19.8% YOY. Carvykti (ciltacabtagene autoleucel), a CAR T cell therapy for MM co-developed by J&J’s Janssen Biotech and China-based Legend Biotech (Nasdaq: LEGN), also performed well, with Q3 2024 sales of USD 334 million and full-year sales of USD 963 million globally.
Immunology Performance
In the immunology field, Stelara (ustekinumab) sales were down 14.7% to USD 2.349 billion in Q3 2024, impacted by generic erosion.
2025 Outlook
J&J provided guidance for 2025, projecting operational sales growth of 2.5% to 3.5%. This outlook reflects the company’s continued investment in innovation and strategic growth initiatives across its business segments.-Fineline Info & Tech
Leave a Reply